Thresholds in disease activity for switching biologics in rheumatoid arthritis patients: Experience from a large US cohort

Arthritis Care and Research

Volumn 63, Issue 12, 2011, Pages 1672-1679

  Zhang, Jie ^a   Shan, Ying ^b   Reed, George ^b   Kremer, Joel ^c   Greenberg, Jeffrey D ^d   Baumgartner, Scott ^e   Curtis, Jeffrey R ^a  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c ALBANY MEDICAL COLLEGE   (United States)

^d NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^e AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL PRACTICE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OBSERVATIONAL STUDY; PROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME; UNITED STATES; AGED; DRUG ANTAGONISM; DRUG SUBSTITUTION; FEMALE; HOSPITALIZATION; IMMUNOLOGY; MALE; MIDDLE AGED; PREDICTIVE VALUE; QUESTIONNAIRE; REGISTER; STATISTICAL MODEL; TIME;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL AGENTS; DRUG SUBSTITUTION; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; QUESTIONNAIRES; REGISTRIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; UNITED STATES;

EID: 84863012741     PISSN: 21514658     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/acr.20643     Document Type: Article

References (27)

1. Yazici Y. Treatment of rheumatoid arthritis: we are getting there. Lancet 2009;374:178-80.
2. Finckh A, Ciurea A, Brulhart L, Moller B, Walker UA, Courvoisier D, et al. Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent? Ann Rheum Dis 2010;69:387-93.
3. Hyrich KL, Lunt M, Dixon WG, Watson KD, Symmons DP. Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug. Rheumatology (Oxford) 2008;47:1000-5. (Pubitemid 351865923)
4. Hjardem E, Ostergaard M, Podenphant J, Tarp U, Andersen LS, Bing J, et al. Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor a inhibitor? Ann Rheum Dis 2007;66: 1184-9. (Pubitemid 47309735)
5. Smolen JS, Kay J, Doyle MK, Landewe R, Matteson EL, Wol-lenhaupt J, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor a inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 2009; 374:210-21.
6. Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor a inhibition. N Engl J Med 2005;353: 1114-23. (Pubitemid 41317434)
7. Hyrich KL, Lunt M, Watson KD, Symmons DP, Silman AJ, for the British Society for Rheumatology Biologics Register. Outcomes after switching from one anti-tumor necrosis factor a agent to a second anti-tumor necrosis factor a agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 2007;56:13-20. (Pubitemid 46106174)
8. Favalli EG, Arreghini M, Arnoldi C, Panni B, Marchesoni A, Tosi S, et al. Anti-tumor necrosis factor a switching in rheumatoid arthritis and juvenile chronic arthritis letter. Arthritis Rheum 2004;51:301-2. (Pubitemid 38468719)
9. Bombardieri S, Ruiz AA, Fardellone P, Geusens P, McKenna F, Unnebrink K, et al. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. Rheumatology (Oxford) 2007;46: 1191-9. (Pubitemid 47053782)
10. Van der Bijl AE, Breedveld FC, Antoni CE, Kalden JR, Kary S, Burmester GR, et al. An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status. Clin Rheumatol 2008;27:1021-8.
11. Du Pan SM, Dehler S, Ciurea A, Ziswiler HR, Gabay C, Finckh A, on behalf of the Swiss Clinical Quality Management Physicians. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. Arthritis Rheum 2009;61:560-8.
12. Gomez-Reino JJ, Carmona L. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther 2006;8: R29.
13. Yazici Y, Krasnokutsky S, Barnes JP, Hines PL, Wang J, Rosenblatt L. Changing patterns of tumor necrosis factor inhibitor use in 9074 patients with rheumatoid arthritis. J Rheumatol 2009;36:907-13.
14. Oei HB, Hooker RS, Cipher DJ, Reimold A. High rates of stopping or switching biological medications in veterans with rheumatoid arthritis. Clin Exp Rheumatol 2009;27:926-34.
15. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, et al. Clinical and radio-graphic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the best study): a randomized, controlled trial. Arthritis Rheum 2005;52:3381-90. (Pubitemid 41612204)
16. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis 2010;69:631-7.
17. Bakker MF, Jacobs JW, Verstappen SM, Bijlsma JW. Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility. Ann Rheum Dis 2007;66 Suppl:iii56-60. (Pubitemid 350032636)
18. Kremer J. The CORRONA database. Ann Rheum Dis 2005;64 Suppl:iv37-41. (Pubitemid 41532015)
19. Kremer JM. The CORRONA database. Autoimmun Rev 2006; 5:46-54. (Pubitemid 41759442)
20. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24. (Pubitemid 18091653)
21. Greenberg JD, Harrold LR, Bentley MJ, Kremer J, Reed G, Strand V. Evaluation of composite measures of treatment response without acute-phase reactants in patients with rheumatoid arthritis. Rheumatology (Oxford) 2009;48:686-90.
22. Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Ma-chold K, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 2005;7:R796-806.
23. Studenic P, Smolen JS, Aletaha D. Perception of RA disease activity by patients and physicians: reasons for and estimators of discrepancies abstract. Arthritis Rheum 2010;62 Suppl: S79.
24. Leeb BF, Andel I, Leder S, Leeb BA, Rintelen B. The patient's perspective and rheumatoid arthritis disease activity indexes. Rheumatology (Oxford) 2005;44:360-5. (Pubitemid 40361294)
25. Wolfe F, Michaud K. Resistance of rheumatoid arthritis patients to changing therapy: discordance between disease activity and patients' treatment choices. Arthritis Rheum 2007; 56:2135-42. (Pubitemid 47173560)
26. Van Vollenhoven RF, Klareskog L. Clinical responses to tumor necrosis factor a antagonists do not show a bimodal distribution: data from the Stockholm Tumor Necrosis Factor a Followup Registry. Arthritis Rheum 2003;48:1500-3. (Pubitemid 36682356)
27. Kremer JM, Greenberg J. Interpreting registry-derived drug studies: does societal context matter? editorial. Arthritis Rheum 2009;60:3155-7.